# A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

> **NCT03723395** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 116 (actual)

## Conditions studied

- Drug-drug Interaction

## Interventions

- **DRUG:** tucatinib
- **DRUG:** itraconazole
- **DRUG:** rifampin
- **DRUG:** gemfibrozil
- **DRUG:** repaglinide
- **DRUG:** tolbutamide
- **DRUG:** midazolam
- **DRUG:** digoxin

## Key facts

- **NCT ID:** NCT03723395
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2018-12-21
- **Final completion:** 2018-12-28
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03723395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03723395, "A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03723395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*